Related Experiment Video
Updated: Feb 28, 2026
06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
1.2K
Proteomics in IDH-mutated diffuse lower-grade glioma: a scoping review
Carl-Johan Kihlstedt1, Anna Dénes1, Alireza Mansouri2
1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Neuro-Oncology Advances
|February 27, 2026
Summary
Isocitrate dehydrogenase-mutated diffuse lower-grade glioma (IDHmut dLGG) has a unique proteome, distinct from other brain tumors. Proteomic analysis reveals altered energy metabolism, offering potential for new biomarkers and therapies.
Area of Science:
- Neuro-oncology
- Proteomics
- Molecular Biology
Background:
- Limited therapeutic options and biomarkers exist for isocitrate dehydrogenase-mutated diffuse lower-grade glioma (IDHmut dLGG).
- Quantitative proteomics has emerged as a tool for discovering novel markers and drug targets in various diseases.
- This review focuses on summarizing current proteomic findings specifically in IDHmut dLGG.
Purpose of the Study:
- To systematically review and summarize the current state of quantitative proteomic research in IDHmut dLGG.
- To identify recurring proteomic alterations and potential biomarkers within IDHmut dLGG.
- To highlight the potential of proteomics for advancing precision medicine in IDHmut dLGG.
Main Methods:
- A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases.
- Studies were included if they utilized quantitative proteomics (liquid chromatography-mass spectrometry) in adult human IDHmut dLGG samples.
- Exclusion criteria included high-grade gliomas, non-IDHmut samples, xenografts, cell lines, and review articles, adhering to PRISMA-ScR guidelines.
Main Results:
- Thirteen studies met the inclusion criteria, with most employing cross-sectional designs and diverse sample types (cerebrospinal fluid, fresh frozen tissue, FFPE tissue).
- A significant heterogeneity in study aims and methodologies was observed.
- The most consistent finding across studies was altered energy metabolism, particularly within the tricarboxylic acid cycle, distinguishing IDHmut dLGG from IDH-wildtype gliomas and other brain tumors.
Conclusions:
- IDHmut dLGG exhibits a distinct proteomic profile that holds promise for biomarker and therapeutic development.
- Proteomic data suggests a reliance on glutamate metabolism for energy production via the citric acid cycle.
- Despite current fragmentation, advancements in proteomics, especially with FFPE samples, can drive large-scale studies and precision medicine for IDHmut dLGG.
